Replies to post #2721 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

IDIX’s Drug Portfolio

[Updated for advances in IDX375, IDX320, and NS5a programs.]


Notes:

• Tyzeka is licensed to NVS; IDIX receives royalties of approximately $4M/year.

• IDX899 is licensed to Viiv Healthcare, the joint venture of GSK and PFE.